[1] | Toth, P. (2005). The good cholesterol: high-density lipoprotein. Circulation, 111(5):e89-e91. |
[2] | Goldbourt, U. & Medalie, J.H. (1979). High density lipoproteins and incidence of coronary heart disease. The Israeli Ischemic Heart Disease Study. Am J Epidemiol., 109:296. |
[3] | Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.P., & Dawber T.R. (1977). High density lipoproteins as a protective factor against coronary heart disease. The Framingham study. Am J Med., 62:707. |
[4] | Miller, G.J., & Miller, N.E. (1975) Plasma high density lipoprotein concentration and development of ischemic heart-disease. Lancer I., 16. |
[5] | Patsch, J. R., Gotto, A. M., Olivecrona, T., & Eisenberg S. (1978). Formation of high density lipoprotein like particle during lipolysis of very low density lipoproteins in vitro. Proc Nut/Acud Sci USA, 75,4519 |
[6] | Brugger, P., Kostner, G. M., Kullich, W. C., & Klein, G. (1986). Plasma concentrations of High-Density Lipoprotein (HDL)-2 and HDL-3 in myocardial infarction survivors and in control subjects. Clin. Cardiol., 9:273–276. |
[7] | Berthold, H. K., Parhofer, K. G., Ritter, M. M., Addo, M., Wasmuth, J. C., Schliefer, K.,… Spengler, U. (1999). Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med., 246(6):567–75. |
[8] | Kostner, G. M., Molinari, E., & Pichler, P. (1985). Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol. Clin chim Acta., 148:139–147 |
[9] | Roeschlau, P., Bernt, E., & Gruber, W. (1974). Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem., 12(5):226. |
[10] | Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W., & Fu, P. C. (1974). Enzymatic determination of total serum cholesterol. Clin Chem., 20(4):470–475. |
[11] | Trinder, P. (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem., 6:24–27. |
[12] | Wahlefeld, A. W., & Bergmeyer, H. U. (1974). Methods of enzymatic analysis. 2nd English ed. New York, NY: Academic Press Inc, 1974:1831. |
[13] | Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18(6):499–502. |
[14] | Peterson, J. I., & Young, D. S. (1958). Anal Biochemistry, 23:301. |
[15] | Schmidt, F. H. (1961). Klin Wschr, 39:1244. |
[16] | Lewis, G. F. & Rader, D. J. (2005). New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res., 96:1221–32. |
[17] | Rose, H., Hoy, J., & Woolley, I. (2008). HIV infection and high density lipoprotein metabolism. Atherosclerosis, 199:79–86. |
[18] | Guerin, M., Le Goff, W., & Lassel, T. S. (2001). Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol., 21:282–8. |
[19] | Grunfeld, C., Pang, M., & Doerrler, W. (1992). Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab., 74:1045–1052. |
[20] | Malan, N., Krantz, E., David, N., Kastango, K., & Frederick, D. (2006). Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5–8 February 2006; Denver, Colorado, United States of America. |
[21] | Johnson, M. A., Gathe, J. C. Jr., Podzamczer, D., Molina, J. M., & Naylor, C. T. (2006). A once daily lopinavir / ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr., 43:153–160. |
[22] | van der Valk, M., Kastelein, J. J., Murphy, R. L., van Leth, F., & Katlama, C. (2001). Nevirapinecontaining antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS, 15:2407–2414. |
[23] | Sweetnam, P. M., Bolton, C. H., Yarnell, J. W., Bainton, D., Baker, I. A., Elwood P. C., & Miller, N. E. (1994). Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The caerphilly and speedwell collaborative heart disease studies. Circulation, 90:769–774. |
[24] | Zangerle, R., Sarcletti, M., & Gallati, H. (1994). Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr., 11:1149–1156. |
[25] | Freeman, D. J., Griffin, B. A., & Murphy, E. (1993). Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest., 23:630–640. |
[26] | Schmitz, M., Michl, G. M., Walli, R., Bogner, J., Bedynek, A., Seidel, D.,… Goebel, F. D. (2001). Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. Journal of acquired immune deficiency syndromes (JAIDS), 26:225–235. |
[27] | Demant, T., Carlson, L. A., & Holmquist, L. (1988). Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and the effect of hepatic lipase on high density lipoprotein. J Lipid Res., 29:1603–11 |
[28] | Beisiegel, U., Weber, W., & Bengtsson, O. G. (1991). Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA, 88:8342–6. |
[29] | Baril, L., Idhammou, A., & Beucler, I. (1999). Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PI-treated patients [abstract 664]? 6th conference on retroviruses and opportunistic infections, Chicago, Illinois, U.S.A. |
[30] | Purnell, J. Q., Zambon, A., & Kn/./opp, R. H. (2000). Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS, 14:53–7 |
[31] | Swinkels, D. W., Hendriks, J. C., & Demacker, P. N. (1990). Differences in metabolism of three low density lipoprotein sub-fractions in Hep G2 cells. Biochim Biophys Acta., 1047:212–22. |
[32] | Taskinen, M. R. (1995). Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol., 6:153–160. |
[33] | Brinkman, K., Smeitink, J. A., & Romijn, J. A. (1999). Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet, 354:1112–15 |
[34] | Grunfeld, C., Kotler, D. P., & Shigenaga, J. K. (1991). Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med., 90:154-62. |
[35] | Grunfeld, C., Dinarello, C. A., & Feingold, K. R. (1991). Tumor necrosis factor-alpha, interleukin-1, and interferon-alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism, 40:894–8. |
[36] | Hellerstein, M. K., Grunfeld, C., and Wu, K. (1993). Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab., 76:559–65. |
[37] | Fernandez-Miranda, C., Castellano, G., & Guijarro, C. (1998). Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol., 93:1901–4. |
[38] | Hamamoto, S., Uchida, Y., & Wada, T. (2005). Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol., 20:204–8. |
[39] | World Health Organisation (1999). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. |
[40] | Yehuda, H. (2009). A Doctor's Diagnosis: prediabetes. Power of Prevention, 1(2):2009. |